Status:
NOT_YET_RECRUITING
First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD)
Lead Sponsor:
Regeneron Pharmaceuticals
Conditions:
Parkinsons Disease
Eligibility:
All Genders
50-80 years
Phase:
PHASE1
Brief Summary
This study is researching an experimental drug called ALN-SNCA (called "study drug"). The study is focused on people with early Parkinson's disease, a disorder of the nervous system that affects movem...
Eligibility Criteria
Inclusion
- Key
- Diagnosis of Parkinson's disease according to the Movement Disorder Society (MDS) criteria, as assessed by the investigator, with bradykinesia plus at least one of the other cardinal signs of Parkinson's disease (resting tremor, rigidity), without any other known or suspected cause of Parkinsonism
- A diagnosis of Parkinson's disease for 4 years or less at the screening visit
- Participant must meet one of the following criteria:
- Currently not receiving any standard-of-care (SoC) therapy for Parkinson's disease, has not been on oral dopaminergic therapy (ie, levodopa, dopamine agonists, or Monoamine Oxidase B \[MAO-B\] inhibitors) prior to dosing, and is not anticipated to require SoC therapy for Parkinson's disease within approximately 6 months following dosing, or
- Has been on a stable regimen of oral dopaminergic therapy for at least 3 months prior to dosing and is not anticipated to require dose adjustments within approximately 6 months following dosing
- BMI ≤35 kg/m\^2 at time of screening visit
- Key
Exclusion
- Medical history indicating a Parkinsonian syndrome other than Parkinson's disease, as defined in the protocol
- Clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease (excluding Parkinson's disease) that, as assessed by the investigator, may confound the results of the study or pose an additional risk to the participant during study participation
- Medical history of brain or spinal disease/injury that would interfere with the Lumbar Puncture (LP) procedure or CSF circulation, as defined in the protocol
- Any contraindications to undergo a brain Magnetic Resonance Imaging (MRI)
- An established allergy or intolerance to lidocaine anesthetic, as defined in the protocol
- History of intolerance to Intrathecal (IT) injection(s)
- Current history of bleeding diatheses that would increase risk of bleeding upon LP
- Has undergone gene therapy, cell therapy or surgical treatment, including deep brain stimulation, for Parkinson's disease
- NOTE: Other Protocol-defined Inclusion/Exclusion Criteria Apply
Key Trial Info
Start Date :
November 24 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 28 2029
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT07216066
Start Date
November 24 2025
End Date
May 28 2029
Last Update
October 14 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.